Posted On: 03/13/2014 8:14:37 PM
Post# of 63741
$BCLI near resistance $0.284
10-Q 11/14/13
November 12, 2013, the number of shares outstanding
of the registrant’s Common Stock, $0.00005 par value per share,
was 176,263,587.
Neuralstem And Brainstorm Cell Therapeutics: The Race To Treat ALS
3/11/2014 10:30:00 AM - Seeking Alpha
BrainStorm Receives Additional $600,000 Non-Dilutive Grant From Israel's Office of the Chief Scientist
2/25/2014 9:15:00 AM - Market Wire
BrainStorm Issues Annual Letter to Shareholders
2/4/2014 8:00:00 AM - Business Wire
BrainStorm Receives US Notice of Allowance for its Key Stem Cell Technology Patent
2/3/2014 8:00:00 AM - Business Wire
BrainStorm Signs Definitive Agreement with Mayo Clinic for ALS Clinical Trial and NurOwn Manufacturing
1/29/2014 8:00:00 AM - Business Wire
10-Q 11/14/13
November 12, 2013, the number of shares outstanding
of the registrant’s Common Stock, $0.00005 par value per share,
was 176,263,587.
Neuralstem And Brainstorm Cell Therapeutics: The Race To Treat ALS
3/11/2014 10:30:00 AM - Seeking Alpha
BrainStorm Receives Additional $600,000 Non-Dilutive Grant From Israel's Office of the Chief Scientist
2/25/2014 9:15:00 AM - Market Wire
BrainStorm Issues Annual Letter to Shareholders
2/4/2014 8:00:00 AM - Business Wire
BrainStorm Receives US Notice of Allowance for its Key Stem Cell Technology Patent
2/3/2014 8:00:00 AM - Business Wire
BrainStorm Signs Definitive Agreement with Mayo Clinic for ALS Clinical Trial and NurOwn Manufacturing
1/29/2014 8:00:00 AM - Business Wire
(0)
(0)Scroll down for more posts ▼
